SDGR — Schrodinger Inc
NASDAQ · Healthcare · Health Information Services
$20.84
+$1.34 (+6.87%)
Schrodinger Inc (SDGR) is a health information services company listed on NASDAQ. It is led by Ramy Farid Ph.D., based in 1540 Broadway, New York, NY, United States, 10036, with about 850 employees. Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Latest reported SDGR revenue for 2025-09-30 was $54.3M. Net income was -$32.8M. Revenue was down 0.8% from 2025-06-30 to 2025-09-30. SDGR currently screens at market cap $1.16B.
Use this SDGR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SDGR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SDGR SEC filings page. Lician reads the product cache first so this HTML stays unique to Schrodinger Inc even when a live quote feed is slow.
About Schrodinger Inc
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
SDGR Key Statistics
Market Cap
$1.16B
Volume
575,786
Previous Close
$18.77
Day Range
$18.86 – $20.18
P/B Ratio
3.48
EPS
-$2.57
Revenue
$207.54M
Net Income
-$187.12M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-4.2%
Profit Margin
-90.2%
Employees
850
SDGR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $207.54M | $216.67M | $180.96M | $137.93M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$187.12M | $40.72M | -$149.19M | -$101.22M |
| EPS (Diluted) | -$2.57 | $0.54 | -$2.10 | -$1.42 |
Total Assets
$823.23M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$147.33M
Operating Cash Flow
-$157.37M
Free Cash Flow
$0.00
Schrodinger Inc Company Information
- CEO, President & Director
- Ramy Farid Ph.D.
- Headquarters
- 1540 Broadway, New York, NY, United States, 10036
- Website
- www.schrodinger.com
- Phone
- 212 295 5800
- IPO / Founded
- 2020-02-06
- Sector
- Healthcare
- Industry
- Health Information Services